Etude d’impact de la communication menée auprès des médecins prescripteurs d’Epitomax® et ses génériques en France

Study identification

• EU PAS number:
  EUPAS24731
• Study ID:
  31433
• Official title and acronym:
  Etude d’impact de la communication menée auprès des médecins prescripteurs d’Epitomax® et ses génériques en France
• DARWIN EU® study:
  No
• Study countries:
  France
• Study description:
  No information provided.
• Study status:
  Finalised

Research institutions and networks

Institutions

NA (database study]

Study timelines

Date when funding contract was signed

Planned:05/05/2017

Actual:05/05/2017

Study start date

Planned:31/10/2017

Actual:31/10/2017

Date of final study report

Planned:28/12/2017

Actual:07/02/2018

Sources of funding

Pharmaceutical company and other private sector 

More details on funding

Accord Healthcare, Arrow, Biogaran, EG Labo, Janssen, Sandoz, Mylan, Zydus

Regulatory

• Was the study required by a regulatory body?:
  Yes
• Is the study required by a Risk Management Plan (RMP)?:
  Not applicable